Clinical Trial Update: H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel [Phase 4]

View source ↗

Summary

Phase 4 study evaluating how H2 haplotype and CYP3A polymorphisms affect the antiplatelet response to clopidogrel in patients with coronary artery disease under…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Conditions: Coronary Artery Disease, Elective Percutaneous Coronary Intervention | Phase 4 | Status: COMPLETED